ABOS
NASDAQAcumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc. (ABOS) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 11 wire items for ABOS, including 6 SEC filings, 2 earnings updates and 2 analyst ratings. The most recent was published Nov 5, 2026.
Financial highlights
Full financials- Net income, TTM
- -$103.96M
- Free cash flow, TTM
- -$87.95M
- Cash
- $53.08M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks32+100%
2026-05-172026-11-08
Mix1490d
- SEC Filings7(50%)
- Earnings3(21%)
- Other2(14%)
- Analyst2(14%)
Activity · 52 weeks8842 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECAcumen Pharmaceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- ANALYSTAcumen Pharmaceuticals downgraded by BofA Securities with a new price targetBofA Securities downgraded Acumen Pharmaceuticals from Buy to Underperform and set a new price target of $1.00
- ANALYSTAcumen Pharmaceuticals downgraded by Stifel with a new price targetStifel downgraded Acumen Pharmaceuticals from Buy to Hold and set a new price target of $1.00
- SECAcumen Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- PRAcumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months compared to placebo at either dose; key secondary endpoints, including CDR-SB, also did not achieve statistical significance -- -- Acumen to cease clinical development of sabirnetug, preserve cash and explore strategic options -- NEWTON, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs)
- SECSEC Form EFFECT filed by Acumen Pharmaceuticals Inc.EFFECT - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECSEC Form S-3 filed by Acumen Pharmaceuticals Inc.S-3 - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECSEC Form 10-Q filed by Acumen Pharmaceuticals Inc.10-Q - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECSEC Form 8-K filed by Acumen Pharmaceuticals Inc.8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- PRAcumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business HighlightsExpect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in November 2026IND filing for the Enhanced Brain Delivery™ (EBD®) program lead clinical candidate targeted for mid-2027Cash, cash equivalents and marketable securities of $78.6 million as of September 30, 2026, expected to support current clinical and operational activities into early 2027Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeuti
- PRAcumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026NEWTON, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report third quarter financial results on Monday, Oct. 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one
- SECAcumen Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- PRAcumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that the Company will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance. The webcast will be available via this link. An archived version of the webcast will b
- PRAcumen Pharmaceuticals to Participate in Upcoming Investor ConferencesNEWTON, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in the following upcoming investor conferences. Cantor Global Healthcare Conference 2026 Date/Time: Fireside chat on Wednesday, September 9, 2026 at 3:55 p.m. ET Citi’s 2026 Biopharma Back to School Conference Date/Time: Fireside chat on Thursday, September 10, 2026 at 8:40 a.m. ET The live webcasts may be accessed under the Investors tab on www.acumenpharm.com and will be archived f
- SECSEC Form S-8 filed by Acumen Pharmaceuticals Inc.S-8 - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECSEC Form 10-Q filed by Acumen Pharmaceuticals Inc.10-Q - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- SECAcumen Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- PRAcumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business HighlightsExpect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026Two candidates nominated for development in Acumen’s Enhanced Brain Delivery™ (EBD™) program; lead clinical candidate IND filing for the EBD program targeted for mid-2027Cash, cash equivalents and marketable securities of $110.2 million as of June 30, 2026, expected to support current clinical and operational activities into early 2027Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-s
- PRAcumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026NEWTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report second quarter financial results on Wednesday, Aug. 12, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least
- INSIDERDirector Porter Derrell exercised 19,500 shares at a strike of $1.07 and sold $75,240 worth of shares (32,300 units at $2.33), decreasing direct ownership by 27% to 35,500 units (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- SECSEC Form 144 filed by Acumen Pharmaceuticals Inc.144 - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
- SECAcumen Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
- INSIDERDirector Fountain Nathan B sold $14,273 worth of shares (6,400 units at $2.23), decreasing direct ownership by 12% to 48,150 units (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- INSIDERDirector Ra Capital Management, L.P. was granted 35,500 shares (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
- INSIDERDirector Fountain Nathan B was granted 35,500 shares, increasing direct ownership by 186% to 54,550 units (SEC Form 4)4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
ABOS FAQ
10 questionsWhat does Acumen Pharmaceuticals Inc. do?
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.What is the latest news on ABOS?
In the last 30 days Quantisnow tracked 11 wire items for ABOS: 6 SEC filings, 2 earnings updates, 2 analyst ratings and 1 press release or news item. The most recent was published on November 5, 2026.Is ABOS profitable?
No. Acumen Pharmaceuticals Inc. reported a net loss of $103.96M for the twelve months ended Sep 30, 2026.How much cash and debt does ABOS have?
Acumen Pharmaceuticals Inc. reported $53.08M in cash and cash equivalents and $26.27M of debt on its most recent balance sheet in SEC filings.Where does ABOS stock trade?
Acumen Pharmaceuticals Inc. (ABOS) is listed on NASDAQ.What sector and industry is ABOS in?
Acumen Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Acumen Pharmaceuticals Inc. go public?
Acumen Pharmaceuticals Inc. (ABOS) completed its IPO in 2021.What are analysts saying about ABOS?
Across the last 8 analyst actions on Acumen Pharmaceuticals Inc., there were 0 upgrades and 2 downgrades. The most recent action was from BofA Securities: Underperform with a $1.00 price target on 2026-11-02.What companies are similar to ABOS?
Notable peers in the same industry include AMGN (Amgen Inc.), ARGX (argenx SE), MRNA (Moderna Inc.), RVMD (Revolution Medicines Inc.), GILD (Gilead Sciences Inc.). Compare ABOS side-by-side with any of them on Quantisnow.How can I track ABOS on Quantisnow?
Quantisnow aggregates Acumen Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABOS to receive live email and push alerts on every new disclosure.